A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Recruiting
The primary objective of this study is to evaluate the effect of setanaxib on biochemical response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Rapid City Medical Center, Rapid City, South Dakota
Conditions: Primary Biliary Cholangitis, Liver Stiffness
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
Recruiting
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/16/2023
Locations: Sanford Health, Sioux Falls, South Dakota
Conditions: Primary Biliary Cholangitis